Enzymes
Enzymes(酶)
Enzymes are very efficient and specific catalyst proteins which react with 1 or few types of substrates in biochemical reactions and are responsible for bringing about almost all of the chemical reactions in living organisms. Enzymes speed up reactions by providing an alternative reaction pathway of lower activation energy. Without enzymes, reactions take place at a rate far too slow for the pace of metabolism which means that they speed up the chemical reactions in living things.
There are 2 types of enzymes, ones that help join specific molecules together to form new molecules & others that help break specific molecules apart into separate molecules. Enzymes play many important roles ouside the cell as well. One of the best examples of this is the digestive system. For instance, it is enzymes in your digestive system that break food down in your digestive system break food down into small molecules that can be absorbed by the body. Some enzymes in your digestive system break down starch, some proteins and others break down fats. The enzymes used to digest our food are extra-cellular since they are located outside our cells & enzymes inside our cells are intra-cellular enzymes. Enzymes are used in ALL chemical reactions in living things; this includes respiration, photosynthesis, movement growth, getting rid of toxic chemicals in the liver and so on. Enzymes are proteins that must have the correct structure to be active. They are very easily affected by heat, pH and heavy metal ions.
Ribonucleoprotein enzyme catalytic activity is located in the protein part but for some the catalytic activity is in the RNA part. A catalyst is any substance which makes a chemical reaction go faster, without itself being changed. A catalyst can be used over and over again in a chemical reaction and does not get used up.
Enzymes lower the amount of activation energy needed by binding to the reactants of the reaction they catalyze, thus speed up the reaction and can process millions of molecules per second. Enzymes are typically large proteins with high molecular weight that permit reactions to go at conditions that the body can tolerate.
Enzyme nomenclature is based on what the enzyme reacts with & how it reacts along with the ending ase.
Enzymes must get over the activation energy hurdle.
Enzymes change how a reaction will proceed which reduces the activation energy and makes it faster. The more we increase the enzyme concentration the faster the reaction rate for non-catalyzed reactions. Enzymes that are catalyzed reactions also increase reaction rate at higher level of concentration but up to a certain point called Vmax which means that the enzyme has reached its maximum point. The reaction is limited by both the concentrations of the enzyme and substrate. Enzymes as catalysts take part in reactions which provide an alternative reaction pathway. Enzymes do not undergo permanent changes and remain unchanged at the end of the reaction. They only change the rate of reaction, not the position of the equilibrium.Enzymes as catalysts are highly selective by only catalysing specific reactions due to the shapes of the enzyme’s molecule.
Enzymes contain a globular protein part called apoenzyme and a non-protein part named cofactor or prosthetic group or metal-ion-activator. Changes in temperature and pH have great influence on the intra- and intermolecular bonds that hold the protein part in their secondary and tertiary structures.
Examples of cofactors are 1. Prosthetic group that are permanently bound to the enzyme. 2. Activator group which are cations (positively charged metal ions) & temporarily bind to the active site of the enzyme. 3.Coenzymes, usually vitamins or made from vitamins which are not permanently bound to the enzyme molecule, but combine with the enzyme-substrate complex temporarily. Enzymes require the presence cofactors before their catalytic activity can be exerted. This entire active complex is referred to as the holoenzyme.
Without enzymes, our guts would take weeks to digest our food, our muscles, nerves and bones would not work properly and so on…
Main Enzyme category groups:
Oxidoreductases:
All enzymes that catalyse oxido-reductions belong in this class. The substrate oxidized is regarded as a hydrogen or electron donor. The classification is based on 'donor:acceptor oxidoreductase'. The common name is 'dehydrogenase', wherever this is possible; as an alternative, 'acceptor reductase' can be used. 'Oxidase' is used only where O2 is an acceptor. Classification is difficult in some cases, because of the lack of specificity towards the acceptor.
Transferases:
Transferases are enzymes that transfer a group, for example, the methyl group or a glycosyl group, from one compound (generally regarded as donor) to another compound (generally regarded as acceptor). The classification is based on the scheme 'donor:acceptor grouptransferase'. The common names are normally formed as 'acceptor grouptransferase' or 'donor grouptransferase'. In many cases, the donor is a cofactor (coenzyme) that carries the group to be transferred. The aminotransferases constitute a special case.
Hydrolases:
These enzymes catalyse the hydrolysis of various bonds. Some of these enzymes pose problems because they have a very wide specificity, and it is not easy to decide if two preparations described by different authors are the same, or if they should be listed under different entries. While the systematic name always includes 'hydrolase', the common name is, in most cases, formed by the name of the substrate with the suffix -ase. It is understood that the name of the substrate with this suffix, and no other indicator, means a hydrolytic enzyme. It should be noted that peptidases have recommended names rather than common names.
Lyases:
Lyases are enzymes that cleave C-C, C-O, C-N and other bonds by means other than by hydrolysis or oxidation. They differ from other enzymes in that two (or more) substrates are involved in one reaction direction, but there is one compound fewer in the other direction. When acting on the single substrate, a molecule is eliminated and this generates either a new double bond or a new ring. The systematic name is formed according to 'substrate group-lyase'. In common names, expressions like decarboxylase, aldolase, etc. are used. 'Dehydratase' is used for those enzymes that eliminate water. In cases where the reverse reaction is the more important, or the only one to be demonstrated, 'synthase' may be used in the name.
Ligases:
Ligases are enzymes that catalyse the joining of two molecules with concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate. 'Ligase' is often used for the common name, but, in a few cases, 'synthase' or 'carboxylase' is used. 'Synthetase' may be used in place of 'synthase' for enzymes in this class.
- 41701(11)
- Activating Transcription Factor(3)
- Adenylate Kinase(10)
- AHCY(3)
- Aldolase(9)
- Asparaginase(5)
- Aurora Kinase(18)
- Beta Lactamase(3)
- Calcium and Integrin Binding(2)
- Calcium/Calmodulin-Dependent Protein Kinase(4)
- Carbonic Anhydrase(49)
- Casein Kinase(36)
- Cathepsin(52)
- Chitinase(5)
- Creatin Kinases(9)
- Cyclin(7)
- Cyclin-Dependent Kinase(18)
- Cyclophilin(23)
- Deaminase(14)
- Decarboxylase(12)
- Dehydrogenase(96)
- Discoidin Domain Receptor Tyrosine Kinase(2)
- DNA Polymerase(4)
- EGF Receptor(3)
- Endonuclease(6)
- Enolase(10)
- Enterokinase(5)
- Epimerase(3)
- Esterase(15)
- FGF Receptors(12)
- FK506 Binding Protein(10)
- Fructosamine 3 Kinase(2)
- Galactosidase(5)
- Glucosidase(32)
- Gluteradoxin(7)
- Glycogen synthase kinase(2)
- Glycosylase(10)
- Glyoxalase(3)
- Granzyme(7)
- Guanylate Kinase(2)
- Heparanase(3)
- Histone Deacetylase(3)
- Hydratase(10)
- Hydrolase(33)
- Hydroxylase(6)
- Isomerase(26)
- Jun N-terminal Kinase(1)
- Jun Proto-Oncogene(2)
- Kallikrein(26)
- Ligase(4)
- Lipase(14)
- Lipocalin(6)
- Lyase(9)
- LYVE1(3)
- Mitogen-Activated Protein Kinase(16)
- MMP(71)
- Mutase(11)
- Natural Enzymes(4)
- Nuclease(18)
- Nucleotidase(4)
- Nudix Type Motif(11)
- Other Enzymes(63)
- Oxidase(23)
- Oxygenase(12)
- Paraoxonase(3)
- Peptidase(41)
- Peroxiredoxin(10)
- Phosphatase(150)
- Phosphorylase(9)
- PI3-kinase(5)
- Polymerase(13)
- PPARG(2)
- Protease(15)
- Proteasome(55)
- Protein Kinase Akt1/PKB alpha(4)
- Protein Kinase-A(7)
- Protein Kinase-C(3)
- Protein Kinases(86)
- Protein Tyrosine Phosphatase(10)
- Reductase(60)
- Secreted Phospholipase A2(10)
- Serine Threonine Kinase(4)
- Sulfatase(8)
- Synthase(23)
- Synthetase(33)
- TGFBR(3)
- TGM2(3)
- TIE1,TIE2
- TIMP(10)
- TPA(4)
- ransaminase
- Transferase(156)
- Tyrosine Kinase(9)
- Ubiquitin Conjugating Enzyme(39)
- Uromodulin(4)
- VEGF Receptors(14)
- Transaminase(19)
- Hexokinase(6)
- TIE1(6)
Enzymes 相关产品(1726)
- GC62145ChiauranibCAS: 1256349-48-0纯度: >99.00%
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy.
- GC62189CD532 hydrochloride纯度: >99.00%
An inhibitor of Aurora A kinase activity and the Aurora A-N-Myc protein-protein interaction
- GC62193(1S,2S)-BortezomibCAS: 1132709-14-8纯度: >96.00%
(1S,2S)-Bortezomib 是 Bortezomib 的对映异构体。Bortezomib 是一种细胞渗透性、可逆性和选择性的蛋白酶体抑制剂,通过靶向苏氨酸残基有效抑制 20S 蛋白酶体 (Ki 为 0.6 nM)。Bortezomib 破坏细胞周期、诱导细胞凋亡以及抑制核因子 NF-κB。Bortezomib 是一种抗癌药物,也是第一种用于人类的蛋白酶体抑制剂。
- GC62210ONX-0914 TFA纯度: >98.00%
A selective inhibitor of the β5i (LMP7) subunit of the immunoproteasome
- GC62239ZetomipzomibCAS: 1629677-75-3
KZR-616 是首创的免疫蛋白酶体 (immunoproteasome) 抑制剂,选择性靶向免疫蛋白酶体亚基 LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) 和 LMP2 (IC50: 131/179 nM=hLMP7/mLMP7)。KZR-616 用于多种自身免疫性疾病的潜力。
- GC62302Cysteine protease inhibitor-2CAS: 612048-23-4
Cysteine protease inhibitor-2 是一种半胱氨酸蛋白酶 (cysteine protease) 抑制剂,详细信息请参考专利文献 US20070032499A1中的化合物 12。
- GC62337CK2 inhibitor 2CAS: 2641079-92-5纯度: >98.00%
CK2 inhibitor 2 是一种有效的,选择性和具有口服活性的 CK2 抑制剂,IC50 值为 0.66 nM。CK2 inhibitor 2 对 Clk2 (IC50=32.69 nM)/CK2 显示出高选择性。 CK2 inhibitor 2 具有良好的抗增殖和抗肿瘤活性。
- GC62345IACS-13909CAS: 2160546-07-4纯度: >99.50%
IACS-13909 is a specific and potent allosteric inhibitor of SHP2 (Src homology 2 domain-containing phosphatase) that suppresses signaling through the MAPK pathway.
- GC62442Casein Kinase inhibitor A51CAS: 2079068-74-7纯度: >98.00%
Casein Kinase inhibitor A51 是一种有效且具有口服活性的酪蛋白激酶 1α (CK1α) 抑制剂。Casein Kinase inhibitor A51 可诱导白血病细胞凋亡 (apoptosis),并具有有效的抗白血病活性。
- GC62551β-HydroxypropiovanilloneCAS: 2196-18-1纯度: >98.00%
β-Hydroxypropiovanillone 是一种天然化合物,对 α-葡萄糖苷酶 (α-glucosidase) 具有明显的浓度依赖性抑制作用 (IC50=257.8 μg/mL)。
- GC62570SHP2-IN-6 hydrochlorideCAS: 2169223-49-6纯度: >98.50%
SHP2-IN-6 hydrochloride 是一种有效的 SHP2 抑制剂,IC50 值为 25.8 nM,详细信息请参见专利 WO2017211303A1,compound 7。
- GC62677IcerguastatCAS: 951441-04-6纯度: >99.50%
Sephin-1 (NSC-65390) is a selective inhibitor of a holophosphatase, a small molecule that safely and selectively inhibits a regulatory subunit of protein phosphatase 1 in vivo. Sephin-1 (NSC-65390) selectively bounds and inhibits the stress-induced PPP1R15A.
- GC62687RazuprotafibCAS: 1008510-37-9纯度: >97%
Razuprotafib (AKB-9778) 是 VE-PTP (HPTPß) 催化活性的有效选择性抑制剂 (IC50=17 pM),促进 TIE2 活化,增强 ANG1 诱导的 TIE2 活化,并刺激 TIE2 通路中信号分子的磷酸化,包括 AKT、eNOS 和 ERK。Razuprotafib 抑制结构相关磷酸酶 PTP1B,IC50 为 780 nM。除 HPTPΗ (IC50=36 pM) 和 HPTPγ (100 pM) 外,Razuprotafib 对 VE-PTP 具有良好的选择性。
- GC62735(E/Z)-GO289CAS: 694522-87-7纯度: >99.50%
(E/Z)-GO289 potently and selectively inhibits casein kinase 2 (CK2) at an IC50 of 7 nM in vitro kinase assay.
- GC62864BenzolamideCAS: 3368-13-6纯度: >98.00%
Benzolamide (CL11366) 是一种有效的碳酸酐酶 (CA) 抑制剂,抑制hCA I,hCA II,EcoCAγ 和 VchCAγ 的 Ki 值分别为15 nM,9 nM,94 nM 和 78 nM。Benzolamide 还抑制 CAS3,Ki 值为 54 nM。Benzolamide 可用于青光眼和癫痫的研究。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC62145 | Chiauranib | 1256349-48-0 | >99.00% | |
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy. | ||||
| GC62189 | CD532 hydrochloride | - | >99.00% | |
An inhibitor of Aurora A kinase activity and the Aurora A-N-Myc protein-protein interaction | ||||
| GC62191 | TD52 | 1798328-24-1 | >99.00% | |
A derivative of erlotinib | ||||
| GC62193 | (1S,2S)-Bortezomib | 1132709-14-8 | >96.00% | |
(1S,2S)-Bortezomib 是 Bortezomib 的对映异构体。Bortezomib 是一种细胞渗透性、可逆性和选择性的蛋白酶体抑制剂,通过靶向苏氨酸残基有效抑制 20S 蛋白酶体 (Ki 为 0.6 nM)。Bortezomib 破坏细胞周期、诱导细胞凋亡以及抑制核因子 NF-κB。Bortezomib 是一种抗癌药物,也是第一种用于人类的蛋白酶体抑制剂。 | ||||
| GC62210 | ONX-0914 TFA | - | >98.00% | |
A selective inhibitor of the β5i (LMP7) subunit of the immunoproteasome | ||||
| GC62239 | Zetomipzomib | 1629677-75-3 | - | |
KZR-616 是首创的免疫蛋白酶体 (immunoproteasome) 抑制剂,选择性靶向免疫蛋白酶体亚基 LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) 和 LMP2 (IC50: 131/179 nM=hLMP7/mLMP7)。KZR-616 用于多种自身免疫性疾病的潜力。 | ||||
| GC62286 | NCGC00378430 | 920650-00-6 | >99.50% | |
NCGC00378430是一种有效的SIX1/EYA2相互作用抑制剂。 | ||||
| GC62302 | Cysteine protease inhibitor-2 | 612048-23-4 | - | |
Cysteine protease inhibitor-2 是一种半胱氨酸蛋白酶 (cysteine protease) 抑制剂,详细信息请参考专利文献 US20070032499A1中的化合物 12。 | ||||
| GC62337 | CK2 inhibitor 2 | 2641079-92-5 | >98.00% | |
CK2 inhibitor 2 是一种有效的,选择性和具有口服活性的 CK2 抑制剂,IC50 值为 0.66 nM。CK2 inhibitor 2 对 Clk2 (IC50=32.69 nM)/CK2 显示出高选择性。 CK2 inhibitor 2 具有良好的抗增殖和抗肿瘤活性。 | ||||
| GC62345 | IACS-13909 | 2160546-07-4 | >99.50% | |
IACS-13909 is a specific and potent allosteric inhibitor of SHP2 (Src homology 2 domain-containing phosphatase) that suppresses signaling through the MAPK pathway. | ||||
| GC62347 | CMC2.24 | 1255639-43-0 | >96.00% | |
CMC2.24 (TRB-N0224) 是一种口服活性三羰基甲烷制剂,通过抑制 Ras 及其下游效应子 ERK1/2 途径对小鼠胰腺肿瘤有效。CMC2.24 也是一种有效的锌依赖性 MMPs 抑制剂,IC50 范围为 2.0-69 μM。CMC2.24 通过恢复软骨内稳态和通过NF-κB/HIF-2α 轴抑制软骨细胞凋亡来减轻骨关节炎的进展。 | ||||
| GC62399 | RA375 | - | - | |
RA375 是 RPN13 (26S 蛋白酶体亚基) 抑制剂。RA375 激活 UPR 信号、ROS 产生和凋亡。RA375 的抗肿瘤活性是 RA190的 10 倍。 | ||||
| GC62433 | AKI603 | 1432515-73-5 | >98.00% | |
AKI-603 is an inhibitor of Aurora kinase A (AurA), which is developed to overcome resistance mediated by BCR-ABL-T315I mutation. | ||||
| GC62442 | Casein Kinase inhibitor A51 | 2079068-74-7 | >98.00% | |
Casein Kinase inhibitor A51 是一种有效且具有口服活性的酪蛋白激酶 1α (CK1α) 抑制剂。Casein Kinase inhibitor A51 可诱导白血病细胞凋亡 (apoptosis),并具有有效的抗白血病活性。 | ||||
| GC62482 | TAS-119 | 1453099-83-6 | >98.00% | |
TAS-119 是一种有效的,选择性的,具有口服活性的 Aurora A 抑制剂,IC50 为 1.0 nM。TAS-119 对 Aurora A 的选择性高于其他蛋白激酶,包括 Aurora B (IC50 为 95 nM)。TAS-119 具有有效的抗肿瘤活性。 | ||||
| GC62487 | POMHEX | 2004714-34-3 | >98.00% | |
POMHEX 是一个消旋混合物,是具有细胞渗透性的 HEX 的 POM 前体药物,是ENO2 的特异性抑制剂。POMHEX 对ENO1 缺失的细胞表现出低纳摩尔级别活性,并对 ENO1 缺失的肿瘤模型表现出良好的抗癌效果。POMHEX 是有效的糖酵解抑制剂。 | ||||
| GC62551 | β-Hydroxypropiovanillone | 2196-18-1 | >98.00% | |
β-Hydroxypropiovanillone 是一种天然化合物,对 α-葡萄糖苷酶 (α-glucosidase) 具有明显的浓度依赖性抑制作用 (IC50=257.8 μg/mL)。 | ||||
| GC62570 | SHP2-IN-6 hydrochloride | 2169223-49-6 | >98.50% | |
SHP2-IN-6 hydrochloride 是一种有效的 SHP2 抑制剂,IC50 值为 25.8 nM,详细信息请参见专利 WO2017211303A1,compound 7。 | ||||
| GC62634 | GSK-2793660 | 1613458-70-0 | - | |
GSK-2793660(游离碱)是一种口服的、不可逆的组织蛋白酶 C (CTSC) 抑制剂。 | ||||
| GC62677 | Icerguastat | 951441-04-6 | >99.50% | |
Sephin-1 (NSC-65390) is a selective inhibitor of a holophosphatase, a small molecule that safely and selectively inhibits a regulatory subunit of protein phosphatase 1 in vivo. Sephin-1 (NSC-65390) selectively bounds and inhibits the stress-induced PPP1R15A. | ||||
| GC62687 | Razuprotafib | 1008510-37-9 | >97% | |
Razuprotafib (AKB-9778) 是 VE-PTP (HPTPß) 催化活性的有效选择性抑制剂 (IC50=17 pM),促进 TIE2 活化,增强 ANG1 诱导的 TIE2 活化,并刺激 TIE2 通路中信号分子的磷酸化,包括 AKT、eNOS 和 ERK。Razuprotafib 抑制结构相关磷酸酶 PTP1B,IC50 为 780 nM。除 HPTPΗ (IC50=36 pM) 和 HPTPγ (100 pM) 外,Razuprotafib 对 VE-PTP 具有良好的选择性。 | ||||
| GC62735 | (E/Z)-GO289 | 694522-87-7 | >99.50% | |
(E/Z)-GO289 potently and selectively inhibits casein kinase 2 (CK2) at an IC50 of 7 nM in vitro kinase assay. | ||||
| GC62864 | Benzolamide | 3368-13-6 | >98.00% | |
Benzolamide (CL11366) 是一种有效的碳酸酐酶 (CA) 抑制剂,抑制hCA I,hCA II,EcoCAγ 和 VchCAγ 的 Ki 值分别为15 nM,9 nM,94 nM 和 78 nM。Benzolamide 还抑制 CAS3,Ki 值为 54 nM。Benzolamide 可用于青光眼和癫痫的研究。 | ||||
| GC62880 | BTX161 | 2052301-24-1 | >98.00% | |
BTX161 一种 Thalidomide 类似物,是一种有效的 CKIα 降解剂。BTX161 比 Lenalidomide更好地介导人类 AML 细胞中 CKIα 的降解,并激活 DNA损伤反应 (DDR) 和 p53,同时稳定 p53 拮抗剂 MDM2。 | ||||
